Results 111 to 120 of about 61,634 (258)

Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma

Swiss Medical Weekly, 2006
DL Goede, RS Hauser
doaj   +1 more source

Expanding the Phenotype of PARK‐PRKN to Spastic Paraplegia: A Report of Two Cases

Movement Disorders Clinical Practice, EarlyView.
Nicolas Geoffre, Thomas Ollivier, Guillaume Baille, Luc Defebvre, Vincent Huin, Eugenie Mutez   +5 more
wiley   +1 more source

Transcranial Pulse Stimulation Enhances Dexterity in Parkinson's Disease: A Randomized Sham‐Controlled Trial

Movement Disorders, EarlyView.
Abstract Background Ultrasound‐based neuromodulation, capable of reaching deep brain areas with high precision, represents cutting‐edge technology in non‐invasive brain stimulation and is investigated as a novel treatment for neurological and psychiatric disorders, including Parkinson's disease (PD).
Eva Matt, Nina Plischek, Michael Mitterwallner, Sonja Radjenovic, Alexandra Weber, Alina Domitner, Gregor Dörl, Anna Zettl, Sarah Osou, Anna Leitgeb, Agnes Santer, Viktoria Winkler, Julia Mandelburger, Heidemarie Zach, Roland Beisteiner   +14 more
wiley   +1 more source

No Dopamine Agonist Modulation of Brain [¹⁸F]FEOBV Binding in Parkinson's Disease. [PDF]

Mol Pharm, 2022
Albin RL, Kanel P, van Laar T, van der Zee S, Roytman S, Koeppe RA, Scott PJH, Bohnen NI.   +7 more
europepmc   +1 more source

Severe Lower Limb and Abdominal Edema Associated with Subcutaneous Apomorphine Infusion

Movement Disorders Clinical Practice, EarlyView.
Guillaume Costentin, David Maltête
wiley   +1 more source

Observations on an Open‐Label Phase 1/2 Dopamine Gene Therapy Trial (OXB‐102/Axo‐Lenti‐PD) in People with Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background SUNRISE‐PD was a dose‐escalating, phase 1/2 study investigating a second‐generation lentiviral vector gene therapy delivering the genes for dopamine synthesis (OXB‐102) to treat Parkinson's disease (PD). The trial was prematurely terminated due to insolvency of the sponsor.
Simon Rowe, Amy Evans, Saeed Kayhanian, Philip C. Buttery, Robert Morris, Katie Andresen, Laura Sherlock, Samuel Hewitt, Tagore Nakornchai, Marwan Hariz, Kyriacos Mitrophanous, Ludvic Zrinzo, Matthew Appleby, Phil Woodgate, Seema Maru, Patricia Limousin, Christine Girges, Thomas Foltynie, Stephane Palfi, Roger A. Barker   +19 more
wiley   +1 more source

Phosphodiesterase 10A (PDE10A): Regulator of Dopamine Agonist-Induced Gene Expression in the Striatum. [PDF]

Cells, 2022
Bonate R, Kurek G, Hrabak M, Patterson S, Padovan-Neto F, West AR, Steiner H.   +6 more
europepmc   +1 more source

Challenges of Pain in Parkinson's Disease: Results from the OCEAN Study

Movement Disorders, EarlyView.
Abstract Background Pain is a common non‐motor symptom in Parkinson’s disease (PD) and is often associated to fluctuations. Objective The OpiCapone Effect on motor fluctuations and pAiN (OCEAN) study evaluated the effect of opicapone on fluctuation‐related pain when added to levodopa therapy in PD patients.
Kallol Ray Chaudhuri, Joaquim J. Ferreira, Angelo Antonini, Olivier Rascol, Monica M. Kurtis, Alexander Storch, José‐Francisco Rocha, Raquel Costa, Diogo Magalhães, Guillermo Castilla‐Fernández, Helena C. Brigas, Joerg Holenz, Per Odin, on behalf of the OCEAN study group   +13 more
wiley   +1 more source

Dopamine Agonist Therapy Induced Fatal Pneumocephalus in Giant Prolactinoma. [PDF]

JCEM Case Rep
M H A, Lila AR, Karlekar M, Memon SS, Barnabas R, Bandgar T.   +5 more
europepmc   +1 more source

Altered Pain Processing Associated with Administration of Dopamine Agonist and Antagonist in Healthy Volunteers. [PDF]

Brain Sci, 2022
Martin SL, Jones AKP, Brown CA, Kobylecki C, Whitaker GA, El-Deredy W, Silverdale MA.   +6 more
europepmc   +1 more source